Evaxion Expands Clinical Trial Duration for EVX-01
Evaxion Biotech A/S (NASDAQ: EVAX), a leader in AI-powered vaccine development, has announced an important decision to extend its ongoing phase 2 clinical trial for its personalized cancer vaccine, EVX-01. Initially planned as a two-year endeavor, the extension will take this study to a total of three years. This strategic move aims to collect comprehensive clinical outcome data over a longer period, further enriching the data package associated with EVX-01.
Insights from Extended Research
The additional year of dosing is poised to offer deeper insights into potential treatment effects and the durability of the immune response triggered by EVX-01. This extension suggests a commitment to thorough research, which could yield valuable information about how these vaccines perform over an extended timeframe.
Current Progress of the Trial
So far, the trial has already demonstrated promising one-year data, illustrating a steady path towards achieving robust two-year data in the latter half of 2025. Participants have shown a reduction in tumor target lesions, indicating a favorable clinical response, which is key as they transition into this extended format of the study.
Patient Experience and Support
Participants in the trial will have the opportunity to enter into a one-year extension after completing the initial two-year protocol, enabling them to continue receiving EVX-01 doses as a standalone treatment. These individuals will be closely monitored to gauge the duration of their clinical response and immune activity, further informing the ongoing study.
Birgitte Rønø's Perspective on the Trial
Birgitte Rønø, Chief Scientific Officer of Evaxion, expressed optimism regarding the trial’s trajectory. She highlighted the encouraging data garnered thus far, noting that patients are responding positively to the treatment with minimal adverse effects. This further extension will allow the company not only to support patients but also to gather more extensive data, potentially uncovering even greater treatment effects than those observed in earlier findings.
Understanding EVX-01 and Its Unique Capabilities
Designed via Evaxion's proprietary AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine targeted at advanced melanoma. Its specificity is rooted in tailoring treatments to the unique tumor and immune characteristics of each patient, enhancing the body's natural ability to combat cancer.
Combination with Keytruda®
The phase 2 trial evaluates the effectiveness of EVX-01 in conjunction with MSD's Keytruda® (pembrolizumab), a well-known anti-PD-1 therapy, among patients suffering from advanced melanoma. Each participant is provided with a vaccine meticulously designed based on their individual biological makeup, showcasing a personalized approach to treatment.
Noteworthy Findings from Interim Data
Interim data gathered during the trial has been compelling. At a recent European Society for Medical Oncology (ESMO) Congress, the study illustrated a 69% overall response rate, with a significant number of participants experiencing a reduction in tumor size. The correlation between the predictions made by the AI-Immunology™ platform and the immune responses to the individualized vaccine components further underscores the innovative nature of this research.
About Evaxion Biotech A/S
Evaxion stands at the forefront of TechBio innovation, leveraging artificial intelligence to revolutionize vaccine development. With its AI-Immunology™ platform, the company is dedicated to decoding the complexities of the human immune system. This commitment has led to a developing pipeline of personalized vaccines aimed at treating multiple types of cancer as well as addressing bacterial and viral infections.
Contact Information
For additional information regarding Evaxion Biotech A/S, individuals can reach out to Mads Kronborg, Vice President of Investor Relations and Communication, at +45 53 54 82 96, or via email at mak@evaxion.ai.
Frequently Asked Questions
What is EVX-01?
EVX-01 is a personalized peptide-based cancer vaccine developed by Evaxion Biotech for the treatment of advanced melanoma.
Why has Evaxion extended the trial?
The extension allows for more comprehensive data collection on treatment effects and immune response durability, contributing to the overall clinical data package.
What positive outcomes have been observed in the trial?
Initial data showed a 69% overall response rate with a reduction in tumor target lesions among participants.
How does AI-Immunology™ contribute to EVX-01?
AI-Immunology™ helps personalize the vaccine by tailoring it to the specific tumor profile and immune characteristics of each patient.
Who should be contacted for more information about Evaxion?
For details, contact Mads Kronborg, Vice President of Investor Relations & Communication at Evaxion Biotech.
